RGC vs. SNY: A Head-to-Head Stock Comparison

Updated on August 23, 2025

Here’s a clear look at RGC and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

RGC is a standard domestic listing, while SNY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	RGC	SNY
Company Name	Regencell Bioscience Holdings Limited	Sanofi
Country	Hong Kong	France
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	6.10 billion USD	123.24 billion USD
Exchange	NasdaqCM	NasdaqGS
Listing Date	July 16, 2021	July 1, 2002
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of RGC and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RGC vs. SNY: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	RGC	SNY
5-Day Price Return	-7.08%	3.98%
13-Week Price Return	20.60%	-7.74%
26-Week Price Return	12,370.00%	-16.60%
52-Week Price Return	5,568.18%	-13.80%
Month-to-Date Return	-5.53%	9.70%
Year-to-Date Return	9,492.31%	-7.73%
10-Day Avg. Volume	0.26M	1.63M
3-Month Avg. Volume	2.29M	2.04M
3-Month Volatility	644.75%	24.79%
Beta	2.37	0.72

Profitability

Return on Equity (TTM)

RGC

-54.75%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

SNY

14.92%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

SNY’s Return on Equity of 14.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

RGC vs. SNY: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

RGC

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

Net Profit Margin data for RGC is currently unavailable.

SNY

20.51%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

A Net Profit Margin of 20.51% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RGC vs. SNY: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

RGC

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

Operating Profit Margin data for RGC is currently unavailable.

SNY

19.08%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

SNY’s Operating Profit Margin of 19.08% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

RGC vs. SNY: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

Symbol	RGC	SNY
Return on Equity (TTM)	-54.75%	14.92%
Return on Assets (TTM)	-51.38%	8.49%
Net Profit Margin (TTM)	--	20.51%
Operating Profit Margin (TTM)	--	19.08%
Gross Profit Margin (TTM)	--	71.85%

Financial Strength

Current Ratio (MRQ)

RGC

42.68

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

SNY

1.27

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

SNY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

RGC vs. SNY: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

RGC

0.00

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

SNY

0.32

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

SNY’s Debt-to-Equity Ratio of 0.32 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC vs. SNY: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

Interest Coverage Ratio data for RGC is currently unavailable.

SNY

22.06

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RGC vs. SNY: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

Symbol	RGC	SNY
Current Ratio (MRQ)	42.68	1.27
Quick Ratio (MRQ)	41.89	0.94
Debt-to-Equity Ratio (MRQ)	0.00	0.32
Interest Coverage Ratio (TTM)	--	22.06

Growth

Revenue Growth

RGC vs. SNY: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RGC vs. SNY: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

SNY

4.56%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

With a Dividend Yield of 4.56%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

RGC vs. SNY: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

SNY

52.56%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RGC vs. SNY: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

Symbol	RGC	SNY
Dividend Yield (TTM)	0.00%	4.56%
Dividend Payout Ratio (TTM)	0.00%	52.56%

Valuation

Price-to-Earnings Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

P/E Ratio data for RGC is currently unavailable.

SNY

9.57

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 9.57 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

RGC vs. SNY: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

P/S Ratio data for RGC is currently unavailable.

SNY

1.96

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

SNY’s P/S Ratio of 1.96 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC vs. SNY: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

RGC

9.57

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

SNY

1.44

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

SNY’s P/B Ratio of 1.44 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

RGC vs. SNY: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

Symbol	RGC	SNY
Price-to-Earnings Ratio (TTM)	--	9.57
Price-to-Sales Ratio (TTM)	--	1.96
Price-to-Book Ratio (MRQ)	9.57	1.44
Price-to-Free Cash Flow Ratio (TTM)	--	10.47